Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 1997

View Archived Issues

Biovail and Technilab Pharma sign marketing agreement

Promising clinical trial results reported for Medeva's Hepagene as vaccine and treatment

Ligand and Lilly enter drug discovery and development alliance for metabolic drugs

Elan: Q3 1997 highlights

Corvas: Q3 1997 highlights

FDA clears Dermagraft-TC for new indication

Imutec's Virulizin approved in Mexico for malignant melanoma

Sankyo isolates antibacterial agent F-12436

ICAM-1/VCAM-1 inhibitors disclosed by Tanabe Seiyaku

Fujirebio cardiovascular agent advances to phase II

Bradykinin antagonists from Pfizer

rhIGF-1 improves lipid profiles in adults with IDDM

Abbott describes new endothelin antagonists

Antiproliferative quinazoline derivatives disclosed at Zeneca

Trazodone evaluated in patients with erectile dysfunction

Novel angiotensin II antagonists for hypertension/CHF

Role of angiotensin II in erectile function investigated

German launch for Xalatan

Elan consolidates U.K. and Irish subsidiaries

GDNF reviewed; potential in Parkinson's disease analyzed

Serdolect now available in Germany for schizophrenia

NeuroSearch evaluates NS-2389 in phase I

Oxis Turbuhaler launched in U.K.

Viagra awarded priority review status by FDA

Lower dose version of Caverject introduced

Encouraging preliminary results for finasteride in androgenic alopecia

Emdogain now available in Switzerland and Austria

KRN-7000 for the treatment of liver metastasis

SmithKline Beecham to copromote Teveten with HMR

Preclinical results with L-methioninase presented at cancer meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld Science
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...